Hypercapnia occurs commonly in modern critical care practice and is usually due to reduced elimination as an effect of decreased alveolar ventilation. Decreased alveolar ventilation may be due to a reduction in minute ventilation or increased dead space ventilation. Occasionally carbon dioxide may be elevated due to increased production in conditions such as hyperpyrexia, shivering, malignant hyperthermia and neuroleptic malignant syndrome.
The management of hypercapnia may depend on whether it is acute or acute on chronic with hypercapnic acidosis or chronic with metabolic compensation. The current ventilation strategy in patients with severe acute respiratory failure is to limit tidal volumes and airway pressures that are considered 'safe'. This approach may cause mild to moderate acute hypercapnia and acidosis, but it is currently accepted as standard care. The use of low volume ventilation is proven beyond a doubt to improve survival in patients with severe respiratory failure compared to conventional higher tidal volumes 1 . Some authors have suggested that hypercapnia and acidosis may be protective by itself, independent of low volume ventilation, and may aid in reducing mortality [2] [3] [4] [5] . These authors have hypothesised that inducing hypercapnia by supplemental carbon dioxide may be beneficial in critically ill patients with acute respiratory failure 3 . Contrarily, other clinicians consider hypercapnic acidosis to be harmful 1, 6, 7 . Several techniques, including extracorporeal carbon dioxide elimination, are being used or evaluated to treat hypercapnic acidosis 1, [7] [8] [9] .
This review aims to define the effects of hypercapnia, with a focus on the pros and cons of clearing carbon dioxide and the modalities that may enhance carbon dioxide clearance.
SEARCH STRATEGY
We searched electronic databases (including Cochrane Library, MEDLINE, EMBASE, Registry of Current Controlled Trials and the Database of Abstracts for Review of Effects) for studies evaluating the effects of carbon dioxide. The search was performed using the following exploded medical subject headings and text words: "carbon dioxide", "hypercarbia", "hypercapnia", "acidosis", "critical care", "extracorporeal membrane oxygenation", "extracorporeal life support", "acute respiratory distress syndrome", "ARDS" and "acute respiratory failure" in isolation and in combination without restrictions. In addition, reference lists of all available review articles and primary studies were searched to identify studies that were not found on computerised searches.
PHYSIOLOGICAL EFFECTS OF HYPERCAPNIA
Hypercapnia and hypercapnic acidosis influence various systems including respiratory, cardiovascular, central nervous, neuromuscular and renal systems ( Table 1) .
Respiratory effects
Acute hypercapnia induces air hunger and increases the respiratory drive. Hypercapnic acidosis potentiates hypoxic pulmonary vasoconstriction with a reduction in the shunt-induced decrease in PaO 2 . Hypercapnia can also reduce alveolar arterial oxygen tension. A combination of these two together has relatively little effect on oxygenation 2 .
Cardiovascular effects
Hypercapnia has many effects on the cardiovascular system by influencing preload, after-load and contractility. Hypercapnic acidosis decreases myocardial contractility but increases heart rate and reduces systemic vascular resistance. The net effect is an increase in systemic cardiac output 10 . Weber et al studied the effects of permissive hypercapnic acidosis on the cardiovascular system. They noted myocardial contractility to be decreased in patients with hypercapnic acidosis. Furthermore, they noted a decrease in mean arterial pressure and an increase in pulmonary arterial pressure 11 . 
Effects on tissue oxygenation
The effects of hypercapnia on oxygen carriage and oxygen dissociation is complex and not fully understood 12 . Acute hypercapnia increases oxygen transport and oxygen off-loading capacity in acute respiratory distress syndrome (ARDS) patients with normal plasma lactate, without increasing oxygen extraction 13 . Hypercapnia and acidaemia shifts the haemoglobin-oxygen dissociation curve rightwards augmenting the tissue release of oxygen 14 . The overall effect is that tissue oxygenation is usually unchanged or improved with permissive hypercapnia due to an increased cardiac output, reduced arterio-venous oxygen content difference and reduced blood lactate concentration 12, 13 .
Central nervous system and neuromuscular junction effects
The effects of hypercapnia on the central nervous system include an elevation of intracranial pressure due to cerebral vasodilation. Acute elevation in carbon dioxide levels may also cause carbon dioxide narcosis. It was also shown that hypercapnia may be deleterious to the neuromuscular junction depressing diaphragmatic function 15, 16 .
Renal effects
Hypercapnic acidosis was shown to reduce renal blood flow 17 with the possible need for increased requirement of haemodialysis 6 .
EXPERIMENTAL STUDIES USING ANIMAL AND CELL CULTURE MODELS TO EVALUATE THE EFFECTS OF HYPERCAPNIA
The effects of hypercapnia and hypercapnic acidosis have been extensively investigated in various animal models of acute lung injury. The implications of hypercapnia and acidosis in acute lung injury are not clear. Some of the experimental data show beneficial effects while others suggest harmful effects.
Laffey et al showed therapeutic hypercapnia to be protective as it attenuated pulmonary inflammation and apoptosis with preserved lung mechanics in an in vivo rabbit model of ischaemia and reperfusion injury 4 . They also showed that buffering hypercapnic acidosis worsens lung injury in a rabbit model of ischaemic reperfusion injury 5 . In their rabbit model of ventilator-induced lung injury, Sinclair et al demonstrated hypercapnic acidosis to be protective 18 . Takeshita et al studied the effects of hypercapnic acidosis on a rabbit model of endotoxin-induced lung injury. They noted hypercapnic acidosis to have anti-inflammatory effects through a mechanism of inhibiting NF-kappaB activation 19 . Costello et al evaluated the effects of hypercapnic acidosis on sepsis-induced lung injury in rats. They found that hypercapnic acidosis attenuates lung injury in both early and prolonged septic lung injury 20 .
Contrary to the above experimental studies, which imply benefit from hypercapnia and hypercapnic acidosis, there are several studies confirming harmful effects of hypercapnia. Pedoto et al have demonstrated hypercapnic acidosis to worsen lung injury and cause haemodynamic instability in a rat model 21 Furthermore, elevated carbon dioxide levels were shown to cause mitochondrial dysfunction and impair cell proliferation 28 .
CLINICAL STUDIES EVALUATING HYPER-CAPNIA AND HYPERCAPNIC ACIDOSIS IN ACUTE LUNG INJURY AND ACUTE RESP-IRATORY DISTRESS SYNDROME
Data from clinical studies on patients with severe respiratory failure are also conflicting. Hickling et al, in their non-comparative observational study, reported improved survival in patients with ARDS where lung-protective ventilation was used with permissive hypercapnia 1, 29 . Kregenow et al, in their retrospective review of an ARDS network study, found that hypercapnic acidosis was associated with reduced 28-day mortality in the 12 ml/kg predicted body weight, tidal volume group after controlling for comorbidities and severity of lung injury 30 . However, there was no survival benefit with hypercapnic acidosis when patients were ventilated with lungprotective tidal volumes (6 ml/kg predicted body weight).
Contrary to these results, prospective randomised controlled trials have raised concerns of the harmful effects of hypercapnia and hypercapnic acidosis 6, 31, 32 . In a multicentric randomised controlled trial, Brochard et al compared low (7 ml/kg predicted body weight, end-inspiratory pressure 25 cmH 2 O) versus conventional tidal volumes (10 ml/kg predicted body weight). The results showed that both groups significantly differed in their tidal volumes (7.1±1.3 vs 10.3±1.7 ml/kg on day 1, P <0.001) and plateau pressures (25.7±5. 0 vs 31.7±6.6 cmH 2 O on day 1, P <0.001), PaCO 2 (59.5±15.0 vs 41.3±7.6 mmHg, P <0.001) and pH (7.28±0.09 vs 7.4±0.09, P <0.001). There were no statistically significant differences in mortality, but a trend towards higher mortality was noted in patients who had hypercapnia and acidosis (46.6 vs 37.9% in control subjects, P=0.38, [relative risk=1.23]). Based on this trend of increased mortality in patients with hypercapnic acidosis, Brochard et al stopped this trial before reaching their planned sample size of 240 patients.
Stewart et al 6 reported a single centre, randomised controlled trial where pressure and volume-limited ventilation (peak inspiratory pressure ≤30 cmH 2 O, tidal volume ≤8 ml/kg) was compared to conventional ventilation (peak inspiratory pressure ≤50 cmH 2 O, tidal volume ≤10-15 ml/kg). The results showed that, in the limited-ventilation group, permissive hypercapnia (arterial carbon dioxide tension >50 mmHg) was more common (52 vs 28% P=0.009), more marked (54.4±18.8 vs 45.7±9.8 mmHg, P=0.002), and more prolonged (146±265 vs 25±22 hours, P=0.017) than in the control group. The numbers of patients who required paralytic agents (23 vs 13, P=0.05) and dialysis for renal failure (13 vs 5, P=0.04) were greater in the pressure and volume-limited ventilation group than in the control group. Mortality was 50% in the limited ventilation group and 47% in the control group (relative risk=1.07; 95% confidence interval, 0.72-1.57; P=0.72).
Brower et al 32 reported a multi-centric randomised controlled trial where traditional tidal volumes (tidal volume 10-12 ml/kg ideal body weight) were compared with low tidal volumes (tidal volume 5-8 ml/kg ideal body weight). The arterial carbon dioxide levels were significantly different between both groups during the first five days (40.1±1.6 and 50.3±3.5 mmHg, respectively; P=0.01). The hospital mortality was 46% in the traditional tidal volume group and 50% in the low tidal volume group.
Based on these data suggesting detrimental effects of hypercapnic acidosis associated with low volume/pressure-limited ventilation, the ARDS Network investigators 1 managed hypercapnic acidosis aggressively, aiming to keep pH >7.30 for all patients, and allowed protocol violations of the tidal volume and airway pressure limits if pH dropped below 7.15. It is interesting to note that the mean PCO 2 level in the low tidal volume ventilation group was 40 mmHg and the mean pH was 7.38 on the first day of the study. The ARDS network authors suggest that this aggressive management of hypercapnic acidosis may be one of the causes for improved survival in their study 1 .
In summary, while the effect of low volume ventilation was proved to be beneficial, the effects of hypercapnia and hypercapnic acidosis remain unclear and potentially harmful. When using low tidal volumes, most clinicians do not tolerate high carbon dioxide when the pH falls below 7.3 1, 7 . Given the available evidence, it appears that mild to moderate hypercapnia (PCO 2 60-65 mmHg), especially when the pH is ≥7.3, is normally well tolerated. However, hypercapnia with hypercapnic acidosis in patients with severe lung injury and ARDS may not be well tolerated with need for sedation and paralytic agents to suppress the respiratory drive with associated adverse effects 33, 34 and may be associated with increased morbidity and mortality 6, 31, 32 .
EXTRACORPOREAL CARBON DIOXIDE CLEARANCE
In the current clinical environment, it remains via ventilation. Various extracorporeal techniques are becoming available and some are being investigated. These techniques include extracorporeal membrane oxygenation (ECMO), where oxygenation, ventilation and cardiac assist can be provided and extracorporeal carbon dioxide (ECCO 2 ) removal devices where partial extracorporeal support is provided mainly to remove carbon dioxide. Oxygenation with a membrane lung in veno-venous ECMO is mainly dependent on the blood flow and carbon dioxide clearance is primarily dependent on the fresh gas flow. It is possible to remove all metabolically produced carbon dioxide using blood flow rates between 1-2 litres/minute of venous blood flow through the membrane lung 35 .
Kolobow developed a membrane lung which was shown to effectively remove carbon dioxide 36 . Indeed, this artificial carbon dioxide removal was so efficient that, when extracorporeal carbon dioxide removal approximated carbon dioxide production, alveolar ventilation could almost be ceased 37 . Clinical application of extracorporeal carbon dioxide removal was first reported in an observational study by Gattinoni et al 38 in an uncontrolled group of patients with severe ARDS. They reported encouraging results in patients with severe ARDS by using this technique as a strategy to 'rest' the lungs. The survival rate of the treated patients in this study was 49%. The blood loss was, however, significant (average blood loss 1800±850 ml/day). Subsequently, Morris et al 39 conducted a randomised clinical trial comparing pressure-controlled inverse ratio ventilation with an extracorporeal carbon dioxide removal technique in patients with ARDS. However, no significant difference in survival was found between the mechanically ventilated patients and those treated with the extracorporeal carbon dioxide removal. The use of ECCO 2 removal did not gain much acceptance due to its complexity and cost, as well as the implications of intervention including high blood flow rates, large cannulae and systemic anticoagulation, with its associated potential complications. Over the last two decades, several less invasive extracorporeal devices were evaluated as alternatives to ECMO support. These are less invasive and less complex devices that may be used to treat hypercapnia and acidosis.
Most of these less invasive devices provide partial extracorporeal support and are efficient in clearing carbon dioxide but do not provide significant oxygenation. The cannulae used to access blood vessels are smaller (14 F) and require minimal anticoagulation similar to renal replacement therapy circuits.
Some of the devices evaluated for extracorporeal carbon dioxide removal include the Interventional Lung Assist (NovaLung GmbH, Hechingen, Germany) 40 , arterio-venous extracorporeal carbon dioxide removal 41, 42 , low flow veno-venous extracorporeal carbon dioxide removal 9 , intra-venacaval oxygenation and carbon dioxide removal 43, 44 , intravascular lung assist 45 , Hattler Respiratory Assist catheter 46 , Decap 47 and Hemolung. Of these devices, the Interventional Lung Assist is the only device that was used in over 1800 patients with hypercapnic respiratory failure with encouraging results 48 . The Interventional Lung Assist is a sophisticated, pumpless extracorporeal arterio-venous carbon dioxide removal device that is driven by the patient's cardiac output and therefore does not require extracorporeal pump assistance.
In addition to treating hypercapnia and hypercapnic acidosis, these less invasive devices are also currently being used in conjunction with mechanical ventilation aiming for 'ultra-protective' mechanical ventilation 8, 9 . Ultra-protective mechanical ventilation may be achieved in patients with ARDS with the use of low flow (0.3-0.5 litres/minute) veno-venous extracorporeal carbon dioxide removal where tidal volumes could be reduced to 4 ml/kg of predicted body weight. This was shown to be associated with superior lung protection compared with 6 ml/kg of predicted body weight 9 . This concept appears promising and may improve the outcome in patients with severe ARDS by reducing ventilator-associated lung injury along with treating hypercapnic acidosis.
CLINICAL CONDITIONS WHERE EXTRA-CORPOREAL CARBON DIOXIDE REMOVAL DEVICES MAY BE OF USE

Acute respiratory distress syndrome and acute lung injury
This is by far the most common condition where extracorporeal carbon dioxide removal devices are used. The use of ECMO and ECCO 2 removal by Gattinoni and Morris did not prove to be effective in improving the survival in patients with severe ARDS. However, the introduction of less invasive devices, such as the Interventional Lung Assist, has prompted clinicians to use these devices, particularly in centres where ECMO is not available. To date, the published literature confirms the increasing use of these devices with encouraging results 49, 50 . A prospective randomised study is currently underway to investigate the effects of a pumpless, extracorporeal interventional lung assist on the implementation of a lung-protective ventilator strategy in patients with ARDS (Registration number NCT00538928).
Exacerbations of asthma and chronic obstructive pulmonary disease
ECCO 2 removal devices show promise in the management of patients with exacerbated chronic obstructive pulmonary disease who fail non-invasive ventilation and who may be unsuitable or unresponsive to invasive mechanical ventilation [51] [52] [53] .
Bridge to lung transplant
The use of Interventional Lung Assist devices to support patients with mild hypoxia and severe hypercapnia refractory to mechanical ventilation proved to be successful when bridging these patients to lung transplantation 54 in one series.
CONCLUSIONS
Despite inconsistent evidence as to whether high levels of carbon dioxide are independently associated with mortality, there is increasing use of devices to assist and control carbon dioxide levels reported in the literature. In conditions where lung-protective mechanical ventilation is not adequate in managing hypercapnic acidosis, extracorporeal carbon dioxide clearing devices are an option. The use of ECMO in such conditions may be beneficial, but is invasive and associated with potential complications. The use of less invasive devices, such as the Interventional Lung Assist, is increasing and several newer, less invasive devices are being introduced into clinical practice. These devices may aid in managing hypercapnic acidosis and may also play a role in instituting ultraprotective lung ventilation.
